An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.
Ainos plans to commence a site initiation visit for the study around April 2025, subject to regulatory approvals. The study aims to further assess the potential of VELDONA in improving salivary gland ...
Immunoglobulin 4-related disease (IgG4-RD) is known for its potential to affect nearly every organ, particularly a preference for large and middle-sized arteries when vascular involvement occurs.